Levosimendan Fresenius Kabi (Levosimendan)

Levosimendan enhances cardiac contractility by binding to troponin C, which increases the sensitivity of the contractile proteins to calcium without raising intracellular calcium levels. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, producing arterial and venous vasodilation that reduces preload and afterload.

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s clinical condition, severity of heart failure, and response to therapy. Physicians typically initiate an intravenous infusion and may adjust the rate or duration according to hemodynamic targets and tolerability.

Safety data for levosimendan in pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it is generally avoided unless no suitable alternatives exist.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Levosimendan differs from traditional inotropes such as dobutamine and milrinone by increasing calcium sensitivity rather than intracellular calcium concentration, which may reduce the risk of calcium‑mediated arrhythmias. It also adds vasodilatory effects through potassium‑channel activation, offering combined inotropic and afterload‑reducing benefits.

Levosimendan Fresenius Kabi must be stored refrigerated at 2‑8 °C. The solution should be kept in its original container, protected from light, and must not be frozen or shaken. If temperature excursions occur, the product should be inspected for visual changes before use.

Levosimendan is administered as an intravenous infusion. After reconstitution according to the manufacturer’s instructions, the infusion is started under continuous cardiac monitoring, with dosage and duration adjusted by the treating physician based on hemodynamic response and tolerability.

The most serious adverse events include ventricular arrhythmias, severe hypotension that may be refractory to standard measures, and myocardial ischemia due to reduced coronary perfusion. Prompt recognition and management of these events are essential during infusion.

Levosimendan should be avoided in patients with known hypersensitivity to the drug, those with severe uncontrolled hypotension, or individuals with significant ventricular arrhythmias. Caution is also advised in patients with severe hepatic impairment or unstable coronary artery disease.